Literature DB >> 9766570

DNA interaction and cytostatic activity of the new liver organotropic complex of cisplatin with glycocholic acid: Bamet-R2.

J J Marin1, R I Macias, J J Criado, A Bueno, M J Monte, M A Serrano.   

Abstract

The aim of this study was to investigate the ability of the new liver organotropic complex of cisplatin with glycocholate (GC), Bamet-R2, to interact with DNA, inhibit its replication and hence reduce tumor-cell proliferation. Changes in the electrophoretic mobility of the open and covalently closed circular forms of the pUC18 plasmid DNA from Escherichia coli, a shift in the denaturation temperature of double-stranded DNA, and ethidium-bromide displacement from DNA binding, were induced by Bamet-R2 and cisplatin, but not by GC. Neutral-red retention was used to measure the number of living cells in culture after long-term (72-hr) exposure to these compounds and to evaluate the effect on cell viability after short-term (6-hr) exposure. Bamet-R2 and cisplatin, but not GC, induced significant inhibition of cell growth. This effect ranged from mild to strong, depending upon the sensitivity of the different cell types as follows: cisplatin, rat hepatocytes in primary culture < rat hepatoma McA-RH7777 cells (rH) < human colon carcinoma LS 174T cells (hCC) < mouse hepatoma Hepa 1-6 cells (mH); Bamet-R2, rat hepatocytes < mH approximately equal to hCC < rH. DNA synthesis was measured by radiolabeled-thymidine incorporation into DNA. Bamet-R2 and cisplatin, but not GC, significantly inhibited the rate of DNA synthesis by these cells. After short-term exposure to Bamet-R2 or GC, no acute cell toxicity was observed, except on hCC cells. By contrast, acute toxicity was induced by cisplatin for all cell types studied. The in vivo anti-tumoral effect was investigated in 3 different strains of mice following s.c. implantation of tumor cells (mouse sarcoma S-18011 cells in Swiss and B6 mice and hCC cells in nude mice). In all 3 models, tumor growth was inhibited by Bamet-R2 and cisplatin to a similar degree. However, signs of toxicity (increases in blood urea concentrations and decreases in packed blood cell volume and in liver, kidney and body weight) and a reduction in survival rate were observed only during cisplatin administration. In sum, these results indicate that this bile-acid derivative can be considered as a cytostatic drug whose potential usefulness deserves further investigation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9766570     DOI: 10.1002/(SICI)1097-0215(19981029)78:3<346::AID-IJC15>3.0.CO;2-4

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs.

Authors:  Timothy C Johnstone; Kogularamanan Suntharalingam; Stephen J Lippard
Journal:  Chem Rev       Date:  2016-02-11       Impact factor: 60.622

Review 2.  Exploitation of bile acid transport systems in prodrug design.

Authors:  Elina Sievänen
Journal:  Molecules       Date:  2007-08-16       Impact factor: 4.411

3.  New fluorescent antitumour cisplatin analogue complexes. Study of the characteristics of their binding to DNA by flow injection analysis.

Authors:  A Alonso; M J Almendral; Y Curto; J J Criado; E Rodríguez; J L Manzano
Journal:  J Fluoresc       Date:  2007-06-08       Impact factor: 2.525

Review 4.  Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.

Authors:  Elisa Lozano; Elisa Herraez; Oscar Briz; Virginia S Robledo; Jorge Hernandez-Iglesias; Ana Gonzalez-Hernandez; Jose J G Marin
Journal:  Biomed Res Int       Date:  2013-07-31       Impact factor: 3.411

Review 5.  Cholangiocarcinoma: Biology, Clinical Management, and Pharmacological Perspectives.

Authors:  Rocio I R Macias
Journal:  ISRN Hepatol       Date:  2014-02-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.